Biological therapies, such as the monoclonal antibodies or soluble cytokine receptors have led to great improvements in the management of several immune-mediated inflammatory diseases including Crohn's disease and ulcerative colitis. Such therapies definitely can modify disease progression, resulting in a reduced need for corticosteroid use, a reduced hospitalization rate, a decreased need for surgery and an increased quality of life [1, 2] . However until now high costs of biologics have also resulted in substantial financial burdens being placed upon individual patients and entire healthcare systems.
The use of antagonists of tumor necrosis factor (TNF-α infliximab, adalimumab, certolizumab and golimumab) has been shown to not only to induce and maintain clinical remission, but also lead to deep remission and a definite change to the IBD cure landscape [1, 2] , especially cases of inflammatory bowel diseases (IBD). However the patents and exclusivity for most biologics have either expired or will expire soon, thereby enabling biotechnological companies to introduce similar biological products. According to the definition proposed by experts from the European Medicines Agency (EMA), biosimilars are similar to other biological products that have already been approved, and do not have any significant differences from the reference product in terms of safety, physicochemical properties and efficacy [3] . Thus biosimilars are not a generic drug.
Recently in Europe, the patent of infliximab expired and the EMA has already approved a biosimilar of this medication on the European market. This was the first approval of a biosimilar of a complex molecule such as monoclonal antibodies. A biosimilar of infliximab (IFX) has been approved in many European countries for the same indications as the IFX counterpart, based on a single equivalence trial conducted in patients with rheumatoid arthritis [4] . From the outset, the possibility of replacing original drugs with biosimilars has raised hopes of lower treatment costs, which would enable the handling of more patients and their concerns. In the early stages of biosimilar use in gastroenterology, data of its efficacy and safety in IBD treatment was limited leading to concerns about indication extrapolation. Almost all gastroenterological societies believed that a bioequivalence study, restricted to rheumatoid patients, should be conducted independently in an IBD group.
With respect to biosimilar infliximab registration, the Working Group of the Polish National Consultant in Gastroenterology, in the absence of data regarding bioequivalence in patients with IBD, does not recommended replacing original biological medicine with its biosimilar analogue in the course of treatment [5] . Most clinicians argue against the interchangeability and automatic substitution of biosimilars [6] .
Currently, mostly retrospective data evaluating efficacy and safety of biosimilars in IBD have been published [7] [8] [9] . The first prospective randomized clinical trials were also recently published, but they are still limited [10, 11] .
Our own centre's retrospective study concerning the efficacy and safety of a biosimilar of infliximab (Inflectra), in a cohort of 176 adult patients with Crohn's disease (CD) over one year of treatment followed by 6 months of observation, suggested similar results in efficacy and safety to a counterpart infliximab and adalimumab, not only in induction and one year CD therapy, but also during the 6-month follow-up [12] . Further retrospective data concerning the efficacy and safety of a biosimilar of infliximab in rescue therapy in the cases of 67 adult patients with severe ulcerative colitis (UC), suggested similar results in efficacy and safety compared to a counterpart infliximab, both in the rescue therapy of UC and during the 6-month follow-up [13] .
Recently, the first interchange results in IBD were also published [14] , showing that switching from Remicade to Remsima was feasible and with few adverse events, such as antidrug antibody formation and loss of response. Another important issue is the lack of long-term follow-up studies for efficacy and safety.
Taking all this into account, further prospective randomized studies for efficacy and safety, as well as immunogenicity and interchangeability with long-term follow-up periods are needed to confidently integrate biosimilars into IBD treatment, especially in terms of future registration of other biosimilars of TNF-α antagonists. 
